Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Diltiazem to Improve Coronary Microvascular Dysfunction
2018-003518-41Phase 2Active
- Sponsor
- Radboudumc
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of diltiazem in Coronary Small Vessel Disease (CMD) and angina pectoris, sponsored by Radboudumc. Primary endpoint: Treatment success proportion. Started Jul 2019; status: active.
02
Drugs
diltiazem
03
Conditions
Coronary Small Vessel Disease (CMD)angina pectoris
Beyond the preview
Go deeper on 2018-003518-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003518-41.